28.12
0.33 (1.19%)
| Previous Close | 27.79 |
| Open | 28.09 |
| Volume | 903,719 |
| Avg. Volume (3M) | 1,291,171 |
| Market Cap | 1,571,305,984 |
| Price / Sales | 4.16 |
| Price / Book | 3.33 |
| 52 Weeks Range | |
| Earnings Date | 24 Feb 2026 |
| Profit Margin | -36.20% |
| Operating Margin (TTM) | -39.67% |
| Diluted EPS (TTM) | -1.69 |
| Quarterly Revenue Growth (YOY) | 55.30% |
| Total Debt/Equity (MRQ) | 21.02% |
| Current Ratio (MRQ) | 8.95 |
| Operating Cash Flow (TTM) | -83.91 M |
| Levered Free Cash Flow (TTM) | -58.77 M |
| Return on Assets (TTM) | -13.36% |
| Return on Equity (TTM) | -27.62% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Devices (US) | Mixed | Bearish |
| Medical Devices (Global) | Mixed | Bearish | |
| Stock | PROCEPT BioRobotics Corporation | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | -0.5 |
| Insider Activity | 1.5 |
| Price Volatility | 0.5 |
| Technical Moving Averages | 1.5 |
| Technical Oscillators | -2.5 |
| Average | 0.10 |
|
PROCEPT BioRobotics Corp is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. It develops, manufactures, and sells the AquaBeam Robotic System and HYDROS Robotic System, which are image-guided, surgical robotic systems for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. Geographically, the company generates a majority of its revenue from the United States and also has a presence in markets outside the U.S. |
|
| Sector | Healthcare |
| Industry | Medical Devices |
| Investment Style | Small Growth |
| % Held by Insiders | 4.22% |
| % Held by Institutions | 93.06% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 62.00 (UBS, 120.48%) | Buy |
| Median | 30.00 (6.69%) | |
| Low | 20.00 (B of A Securities, -28.88%) | Sell |
| Average | 34.00 (20.91%) | |
| Total | 6 Buy, 1 Sell | |
| Avg. Price @ Call | 25.72 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Truist Securities | 02 Mar 2026 | 30.00 (6.69%) | Buy | 25.90 |
| 18 Dec 2025 | 47.00 (67.14%) | Buy | 32.73 | |
| B of A Securities | 26 Feb 2026 | 20.00 (-28.88%) | Sell | 23.63 |
| 08 Dec 2025 | 38.00 (35.14%) | Hold | 34.03 | |
| Leerink Partners | 26 Feb 2026 | 30.00 (6.69%) | Buy | 23.63 |
| Piper Sandler | 26 Feb 2026 | 28.00 (-0.43%) | Buy | 23.63 |
| TD Cowen | 26 Feb 2026 | 34.00 (20.91%) | Buy | 23.63 |
| Wells Fargo | 26 Feb 2026 | 34.00 (20.91%) | Buy | 23.63 |
| UBS | 12 Dec 2025 | 62.00 (120.48%) | Buy | 35.99 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| NOURI ALALEH | 26.76 | - | 4,872 | 130,375 |
| WATERS KEVIN | 26.76 | - | 3,532 | 94,516 |
| Aggregate Net Quantity | 8,404 | |||
| Aggregate Net Value ($) | 224,891 | |||
| Aggregate Avg. Buy ($) | 26.76 | |||
| Aggregate Avg. Sell ($) | - | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| WATERS KEVIN | Officer | 19 Feb 2026 | Acquired (+) | 3,532 | 26.76 | 94,516 |
| NOURI ALALEH | Officer | 19 Feb 2026 | Acquired (+) | 4,872 | 26.76 | 130,375 |
| Date | Type | Details |
|---|---|---|
| 04 Feb 2026 | Announcement | PROCEPT BioRobotics® to Attend the TD Cowen 46th Annual Health Care Conference and the 2026 Leerink Global Healthcare Conference |
| 26 Jan 2026 | Announcement | PROCEPT BioRobotics® to Host 4Q25 Earnings Conference Call on February 24, 2026, and Investor Day on February 25, 2026, in New York City |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |